- Home
- CUE vs PAVS Comparison
CUE vs PAVS Comparison
Compare CUE & PAVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CUE
- PAVS
- Stock Information
- Founded
- CUE 2014
- PAVS 2004
- Country
- CUE United States
- PAVS United States
- Employees
- CUE N/A
- PAVS N/A
- Industry
- CUE Biotechnology: Pharmaceutical Preparations
- PAVS Medicinal Chemicals and Botanical Products
- Sector
- CUE Health Care
- PAVS Health Care
- Exchange
- CUE Nasdaq
- PAVS Nasdaq
- Market Cap
- CUE 59.5M
- PAVS 49.1M
- IPO Year
- CUE 2018
- PAVS 2019
- Fundamental
- Price
- CUE $0.74
- PAVS $0.78
- Analyst Decision
- CUE Strong Buy
- PAVS
- Analyst Count
- CUE 2
- PAVS 0
- Target Price
- CUE $3.00
- PAVS N/A
- AVG Volume (30 Days)
- CUE 127.4K
- PAVS 146.2K
- Earning Date
- CUE 11-13-2025
- PAVS 08-04-2025
- Dividend Yield
- CUE N/A
- PAVS N/A
- EPS Growth
- CUE N/A
- PAVS N/A
- EPS
- CUE N/A
- PAVS N/A
- Revenue
- CUE $8,286,000.00
- PAVS $71,542.00
- Revenue This Year
- CUE N/A
- PAVS N/A
- Revenue Next Year
- CUE $10.19
- PAVS N/A
- P/E Ratio
- CUE N/A
- PAVS N/A
- Revenue Growth
- CUE N/A
- PAVS N/A
- 52 Week Low
- CUE $0.45
- PAVS $0.32
- 52 Week High
- CUE $1.99
- PAVS $1.50
- Technical
- Relative Strength Index (RSI)
- CUE 37.79
- PAVS 48.90
- Support Level
- CUE $0.77
- PAVS $0.76
- Resistance Level
- CUE $0.79
- PAVS $0.90
- Average True Range (ATR)
- CUE 0.03
- PAVS 0.11
- MACD
- CUE -0.01
- PAVS 0.01
- Stochastic Oscillator
- CUE 11.92
- PAVS 27.27
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.
About PAVS Paranovus Entertainment Technology Ltd.
Paranovus Entertainment Technology Ltd, through its subsidiaries, is involved in the AI-powered entertainment industry, to provide users with AI-driven games and applications to deliver immersive and engaging entertainment experiences. It has entered into a software development agreement for the development of 10,000 Lives, a mobile game where players pursue various careers and life goals using a board game mechanic. The group is also involved in an e-commerce business and provides TikTok-related e-commerce solutions for customers.